Howe & Rusling’s Editas Medicine EDIT Stock Holding History

Howe & Rusling’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-25	Closed	–	–	533
2022 Q3	$0	Sell	25 -200	-89%	-$3.12K	﹤0.01%	1091
2022 Q2	$3K	Buy	+225	New	+$3.02K	﹤0.01%	778
2020 Q4	–	Sell	-250	Closed	-$7K	–	949
2020 Q3	$7K	Buy	+250	New	+$8.14K	﹤0.01%	495

Other funds holding EDIT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Howe & Rusling's EDIT Position: Q4 2022 in Review

Howe & Rusling sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 25 shares.

Howe & Rusling first reported a position in EDIT in Q3 2020 and held it in 3 quarters. The position peaked at $7K in Q3 2020. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

Howe & Rusling reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 25 Editas Medicine shares in Q4 2022.
Howe & Rusling first reported a position in Editas Medicine in Q3 2020 and held it in 3 quarters.
Howe & Rusling's Editas Medicine position peaked at $7K in Q3 2020.
250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.